Special Issue

Molecular Research of Genes Involved in Metabolic Diseases

Message from the Guest Editors

Metabolic diseases include a large number of disorders that are related to the alteration of different aspects of metabolism. These diseases include all those associated with cardiometabolic diseases and others related to other metabolites that can cause a disease. This Special Issue aims to include original reports, reviews, and short reports on understanding the potential molecular mechanisms underlying different kind of metabolic diseases related, among others, to diabetes, lipid alterations or obesity. In this issue, we are interested in including studies on the genetic causes, mechanisms involved, and their use as biomarkers in complex or monogenic diseases.

Guest Editors

Dr. Felipe Javier Chaves-Martinez

Genomics and Diabetes Unit, Health Research Institute Clinic Hospital of Valencia-INCLIVA, Menendez Pelayo 4acc, 46010 Valencia, Spain

Dr. Ana-Bárbara García-García

CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), 28029 Madrid, Spain

Deadline for manuscript submissions

closed (28 February 2023)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/95709

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).